Cluster analysis was performed using squared euclidean distance and complete linkage clustering.
. Hyper/hypo methylation related genes were defined as genes whose promoter is located nearby a DMR (within 5kb). The log2 fold change was calculated by the RPKM value change from diagnosis to relapse in this patient. We performed t-test comparing the expression changes of hyper/hypo DMRs related genes versus expression changes of other genes. P-value were derived from t-test. 
Supplementary

SUPPLEMENTARY NOTE 1
The tendency toward hypo or hyper methylation isn't affected by the distribution of methylation sites in the genome or by the bias of the ERRBS assay toward CG rich regions.
We primarily addressed differences between diagnosis and relapse, which are different (not as strong) as those between normal cells (with marked tendency towards very low or very high and homogeneous methylation) and tumors (with more heterogeneity). We plotted the distribution of methylation levels at diagnosis for hypermethylation and hypomethylation DMRs (Supplementary Fig. 2) . We also plotted the distribution of methylation levels at diagnosis for all ERRBS-covered regions (Supplementary Fig. 2 ). These regions were defined as containing at least 5 covered CpGs minimum, separated by less than 250bp between contiguous CpGs, which is similar to the definition of DMRs without methylation ratio cutoff and DMCs requirement. We found that (1) DMR methylation levels at diagnosis span across a broad range (not only extreme hypo or hyper methylation) and (2) DMR methylation levels at diagnosis are not well correlated with ERRBS-covered regions. To answer the reviewer's question, these results suggest that (1) the tendency toward hypo or hyper methylation is not strongly affected by the distribution of low and high methylation sites in the genome and (2) the tendency toward hypo or hyper methylation is not strongly affected by the bias of the ERRBS assay toward CG rich regions.
Methylation signature based on differentially methylated regulatory elements
We identified 107 differentially methylated promoters, 22 enhancers and 118 CTCF binding sites between diagnosis and relapse (>10% DNA methylation changes and P<0.05, paired t-test, two-sided) ( Supplementary Fig. 3, Supplementary Fig. 4a-c 
